In a sometimes contentious hearing, a subcommittee of the US House of Representatives Government Reform committee last week heard testimony and debated whether mifepristone (RU 486) should be removed from the market. Democrats who attended the meeting unanimously advocated letting science and not ideology or politics determine the future use of the medical abortion drug known in the US as Mifeprex.
The hearing was chaired by Rep. Mark Souder (R-IN), chair of the House Criminal Justice, Drug Policy and Human Resources Subcommittee, who repeatedly stated that his opposition to abortion had no relevance to the hearing. Souder said his motivation for calling for the removal of Mifeprex from the market is his concern for women’s health following the deaths of five women out of the almost 600,000 who had used Mifeprex in the United States. All five had taken Mifeprex orally followed by a prostaglandin inserted vaginally. Four of the deaths have been determined to be from a rare bacteria (Clostridium) that has been identified in 30 fatalities, including eight women who had given birth, two who had miscarriages and also in some men.
The subcommittee’s ranking Democrat, Rep. Elijah Cummings (D-MD), questioned why the hearing was focusing on only the deaths from the Clostridium bacteria where mifepristone was taken when there were more fatalities in people who had not been given the drug. Cummings said, “Our focus should be looking at all of the deaths, not bullying FDA” to remove mifepristone from the market. In her testimony before the Committee, Susan Wood, PhD, the former Food and Drug Administration Assistant Commissioner for Women’s, spoke of how the close monitoring of mifepristone has “alerted us that this bacterial infection is present and has caused deaths of other women who have given birth or had a miscarriage – more in fact than the number of women who underwent a medical abortion.” Wood went on to say that we need to improve systems that monitor maternal mortality to determine the impact of Clostridium and to “understand and prevent the other risks that women face with pregnancy.”
Questioning the basis for the hearing, Rep. Henry Waxman, (D-FL), ranking Democrat on the full Government Affairs Committee, said, “The reason I believe we are here...people wanted RU 486 pulled since it was approved.” Waxman further said, “Any regulatory decision on RU 486 must be made based on science and law not politics of the abortion debate.”
1/23/2015 #HeForShe Campaign Launches Pilot Effort Aimed at Institutional Equality - The United Nations' gender equality campaign #HeForShe has launched a new program called IMPACT 10X10X10.
United Nations Goodwill Ambassador Emma Watson, together with UN Women Executive DirectorPhumzile Mlambo-Ngcuka, introduced the one-year pilot effort aimed at encouraging corporations, universities, and governments to play an active role in enhancing women's empowerment and equality in Davos, Switzerland today at the World Economic Forum.
"Women need to be equal participants in our homes, societies, in our governments, and in our workplaces," Watson said.
First introduced in September, HeForShe is a solidarity movement that calls on men and boys to confront gender inequalities that face women and girls globally. . . .
1/22/2015 BREAKING: House to Vote on Abortion Coverage Ban - After they were forced to scrap plans for a 20-week abortion ban, House Republican leaders decided late last night to instead ram through a vote today on a different extreme anti-abortion bill.
House Republicans are now pushing HR 7, a bill promoted as a ban on federal funding of abortion that would actually prevent women from using their own money to purchase health insurance that includes abortion care. . . .
1/22/2015 House Cancels Abortion Ban After GOP Congresswomen Drop Support - House Republicans cancelled plans to vote on a 20-week ban on abortion after Republican Congresswomen removed their names publicly as co-sponsors of the bill.
The vote on the unconstitutional 20-week ban had originally been scheduled for today, the anniversary of Roe v. . . .